A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

NCT07365241 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

531

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: ABBV-706
DRUG: Topotecan
DRUG: Topotecan
DRUG: Lurbinectedin
DRUG: Amrubicin

Sponsor

AbbVie